vs
CORCEPT THERAPEUTICS INC（CORT）与OCTAVE SPECIALTY GROUP INC（OSG）财务数据对比。点击上方公司名可切换其他公司
CORCEPT THERAPEUTICS INC的季度营收约是OCTAVE SPECIALTY GROUP INC的1.9倍（$202.1M vs $104.2M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs -6.6%，领先18.6%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 11.1%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs 17.3%）
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
CORT vs OSG — 直观对比
营收规模更大
CORT
是对方的1.9倍
$104.2M
营收增速更快
OSG
高出54.9%
11.1%
净利率更高
CORT
高出18.6%
-6.6%
两年增速更快
OSG
近两年复合增速
17.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $104.2M |
| 净利润 | $24.3M | $-6.9M |
| 毛利率 | 98.7% | — |
| 营业利润率 | 2.2% | — |
| 净利率 | 12.0% | -6.6% |
| 营收同比 | 11.1% | 66.0% |
| 净利润同比 | -21.0% | — |
| 每股收益（稀释后） | $0.20 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CORTOSG
| Q1 26 | — | $104.2M | ||
| Q4 25 | $202.1M | $66.9M | ||
| Q3 25 | $207.6M | $66.6M | ||
| Q2 25 | $194.4M | $55.0M | ||
| Q1 25 | $157.2M | $62.8M | ||
| Q4 24 | $181.9M | $65.2M | ||
| Q3 24 | $182.5M | $70.0M | ||
| Q2 24 | $163.8M | $51.0M |
净利润CORTOSG
| Q1 26 | — | $-6.9M | ||
| Q4 25 | $24.3M | $-29.7M | ||
| Q3 25 | $19.7M | $-112.6M | ||
| Q2 25 | $35.1M | $-72.7M | ||
| Q1 25 | $20.5M | $-44.7M | ||
| Q4 24 | $30.7M | $-20.9M | ||
| Q3 24 | $47.2M | $-27.5M | ||
| Q2 24 | $35.5M | $-750.0K |
毛利率CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | 98.7% | — | ||
| Q3 25 | 97.8% | — | ||
| Q2 25 | 98.2% | — | ||
| Q1 25 | 98.5% | — | ||
| Q4 24 | 98.4% | — | ||
| Q3 24 | 98.4% | — | ||
| Q2 24 | 98.5% | — |
营业利润率CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | -76.7% | ||
| Q3 25 | 4.9% | -48.2% | ||
| Q2 25 | 13.7% | -41.8% | ||
| Q1 25 | 2.2% | -24.1% | ||
| Q4 24 | 13.9% | -55.5% | ||
| Q3 24 | 25.5% | -29.7% | ||
| Q2 24 | 21.7% | -28.9% |
净利率CORTOSG
| Q1 26 | — | -6.6% | ||
| Q4 25 | 12.0% | -73.8% | ||
| Q3 25 | 9.5% | -169.1% | ||
| Q2 25 | 18.1% | -132.3% | ||
| Q1 25 | 13.1% | -71.3% | ||
| Q4 24 | 16.9% | -55.1% | ||
| Q3 24 | 25.9% | -39.3% | ||
| Q2 24 | 21.7% | -1.5% |
每股收益（稀释后）CORTOSG
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.20 | $-0.82 | ||
| Q3 25 | $0.16 | $-2.35 | ||
| Q2 25 | $0.29 | $-1.54 | ||
| Q1 25 | $0.17 | $-1.22 | ||
| Q4 24 | $0.25 | $-11.75 | ||
| Q3 24 | $0.41 | $-0.63 | ||
| Q2 24 | $0.32 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $372.2M | — |
| 总债务越低越好 | — | $117.1M |
| 股东权益账面价值 | $647.8M | $833.6M |
| 总资产 | $836.7M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $146.4M | ||
| Q3 25 | $421.7M | $27.5M | ||
| Q2 25 | $342.2M | $22.5M | ||
| Q1 25 | $322.8M | $34.1M | ||
| Q4 24 | $383.3M | $157.2M | ||
| Q3 24 | $380.3M | $40.8M | ||
| Q2 24 | $473.2M | $14.6M |
总债务CORTOSG
| Q1 26 | — | $117.1M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $518.0M | ||
| Q2 24 | — | $515.0M |
股东权益CORTOSG
| Q1 26 | — | $833.6M | ||
| Q4 25 | $647.8M | $715.8M | ||
| Q3 25 | $631.9M | $843.4M | ||
| Q2 25 | $635.8M | $859.8M | ||
| Q1 25 | $683.3M | $852.2M | ||
| Q4 24 | $679.6M | $798.4M | ||
| Q3 24 | $638.8M | $1.5B | ||
| Q2 24 | $596.2M | $1.4B |
总资产CORTOSG
| Q1 26 | — | $2.3B | ||
| Q4 25 | $836.7M | $2.2B | ||
| Q3 25 | $823.6M | $2.1B | ||
| Q2 25 | $801.7M | $8.5B | ||
| Q1 25 | $846.5M | $8.3B | ||
| Q4 24 | $840.6M | $8.1B | ||
| Q3 24 | $784.3M | $9.3B | ||
| Q2 24 | $714.6M | $8.2B |
负债/权益比CORTOSG
| Q1 26 | — | 0.14× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | — |
| 自由现金流经营现金流 - 资本支出 | $38.4M | — |
| 自由现金流率自由现金流/营收 | 19.0% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 1.58× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | $38.4M | $-52.3M | ||
| Q3 25 | $54.5M | $-41.2M | ||
| Q2 25 | $43.9M | $2.1M | ||
| Q1 25 | $5.1M | $-12.6M | ||
| Q4 24 | $59.3M | $762.0K | ||
| Q3 24 | $73.8M | $48.9M | ||
| Q2 24 | $41.2M | $20.4M |
自由现金流CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | $38.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $43.9M | — | ||
| Q1 25 | $5.0M | — | ||
| Q4 24 | $59.2M | — | ||
| Q3 24 | $72.2M | — | ||
| Q2 24 | $40.8M | — |
自由现金流率CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | 19.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 39.5% | — | ||
| Q2 24 | 24.9% | — |
资本支出强度CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.3% | — |
现金转化率CORTOSG
| Q1 26 | — | — | ||
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 1.93× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CORT
暂无分部数据
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
